LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
IPO Year:
Exchange: NASDAQ
Website: lensar.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/22/2021 | $15.00 | Buy | BTIG |